Sarah W. S. Ng
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Sarah W. S. Ng has a total of 163 co-authors. Here are the top co-authors by number of shared publications:
- Alexander William Wyatt
Vancouver Prostate Centre, Department of Urologic Sciences, University of British Columbia, Vancouver, Canada
116 shared publications - Cameron Herberts
Vancouver Prostate Centre, Department of Urologic Sciences, University of British Columbia, Vancouver, Canada
116 shared publications - Edmond Michael Kwan
Eastern Health Clinical School Monash University Melbourne Australia
112 shared publications - Matti Annala
Faculty of Medicine and Health Technology, Tampere University and Tays Cancer Centre, Tampere, Finland
112 shared publications - Gráinne Donnellan
Vancouver Prostate Centre, Department of Urologic Sciences, University of British Columbia, Vancouver, Canada
111 shared publications - Sofie H. Tolmeijer
Vancouver Prostate Centre, Department of Urologic Sciences, University of British Columbia, Vancouver, Canada
105 shared publications
Latest Publications
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figures 1-12 from Plasma Cell–Free DNA Chromatin Immunoprecipitation Profiling Depicts Phenotypic and Clinical Heterogeneity in Advanced Prostate Cancer
Supplementary Figures 1-12 with embedded captions.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures 1-12 from Plasma Cell–Free DNA Chromatin Immunoprecipitation Profiling Depicts Phenotypic and Clinical Heterogeneity in Advanced Prostate Cancer
Supplementary Figures 1-12 with embedded captions.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Methods from Early On-treatment Changes in Circulating Tumor DNA Fraction and Response to Enzalutamide or Abiraterone in Metastatic Castration-Resistant Prostate Cancer
Additional methodological details
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Methods from Early On-treatment Changes in Circulating Tumor DNA Fraction and Response to Enzalutamide or Abiraterone in Metastatic Castration-Resistant Prostate Cancer
Additional methodological details
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S8 from Early On-treatment Changes in Circulating Tumor DNA Fraction and Response to Enzalutamide or Abiraterone in Metastatic Castration-Resistant Prostate Cancer
Baseline circulating tumor DNA fraction according to detection status at 4 weeks
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S8 from Early On-treatment Changes in Circulating Tumor DNA Fraction and Response to Enzalutamide or Abiraterone in Metastatic Castration-Resistant Prostate Cancer
Baseline circulating tumor DNA fraction according to detection status at 4 weeks
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Early On-treatment Changes in Circulating Tumor DNA Fraction and Response to Enzalutamide or Abiraterone in Metastatic Castration-Resistant Prostate Cancer
Evidence for ctDNA estimates per patient per timepoint
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Early On-treatment Changes in Circulating Tumor DNA Fraction and Response to Enzalutamide or Abiraterone in Metastatic Castration-Resistant Prostate Cancer
Evidence for ctDNA estimates per patient per timepoint
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from Early On-treatment Changes in Circulating Tumor DNA Fraction and Response to Enzalutamide or Abiraterone in Metastatic Castration-Resistant Prostate Cancer
Frequency of recurrent somatic alterations compared to published cohorts
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from Early On-treatment Changes in Circulating Tumor DNA Fraction and Response to Enzalutamide or Abiraterone in Metastatic Castration-Resistant Prostate Cancer
Frequency of recurrent somatic alterations compared to published cohorts
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from Early On-treatment Changes in Circulating Tumor DNA Fraction and Response to Enzalutamide or Abiraterone in Metastatic Castration-Resistant Prostate Cancer
Oncoprint showing the copy number alterations, structural variants and mutations per patient at baseline
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from Early On-treatment Changes in Circulating Tumor DNA Fraction and Response to Enzalutamide or Abiraterone in Metastatic Castration-Resistant Prostate Cancer
Oncoprint showing the copy number alterations, structural variants and mutations per patient at baseline
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Early On-treatment Changes in Circulating Tumor DNA Fraction and Response to Enzalutamide or Abiraterone in Metastatic Castration-Resistant Prostate Cancer
Representativeness of study participants
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Early On-treatment Changes in Circulating Tumor DNA Fraction and Response to Enzalutamide or Abiraterone in Metastatic Castration-Resistant Prostate Cancer
Representativeness of study participants
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S7 from Early On-treatment Changes in Circulating Tumor DNA Fraction and Response to Enzalutamide or Abiraterone in Metastatic Castration-Resistant Prostate Cancer
On-treatment ctDNA fraction, PSA responses and baseline genomic and clinical features
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S7 from Early On-treatment Changes in Circulating Tumor DNA Fraction and Response to Enzalutamide or Abiraterone in Metastatic Castration-Resistant Prostate Cancer
On-treatment ctDNA fraction, PSA responses and baseline genomic and clinical features
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S9 from Early On-treatment Changes in Circulating Tumor DNA Fraction and Response to Enzalutamide or Abiraterone in Metastatic Castration-Resistant Prostate Cancer
Changes in PSA levels between baseline and 4 weeks on-treatment in the different ctDNA kinetics groups
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S9 from Early On-treatment Changes in Circulating Tumor DNA Fraction and Response to Enzalutamide or Abiraterone in Metastatic Castration-Resistant Prostate Cancer
Changes in PSA levels between baseline and 4 weeks on-treatment in the different ctDNA kinetics groups